According to results from the APPOSITION III study, which was presented at the Transcatheter Cardiovascular Therapeutics meeting (13–17 September, Washington, USA), the Stentys’ Self-Apposing stent is associated with a low rate of mortality at two years after a myocardial infarction. APPOSITION III is the largest trial ever conducted to evaluate the use of a self-apposing stent in primary percutaneous coronary intervention (PCI).
A press release reports that APPOSITION III is an international, prospective, single-arm and multicentre clinical study. The rate of MACE (defined as the composite of cardiac death, target-vessel myocardial infarction, emergent by-pass and clinically driven target lesion revascularisation), was 11.2% (compared to 9.3% at one year) and cardiac death at two years was 2.3% (compared to 2% at one year) in patients who received the Self-Apposing stent when undergoing primary PCI.
Study presenter Maik Grundeken (Amsterdam Medical Center , Amsterdam, the Netherlands) says: “The low rate of cardiac death, myocardial infarction and stent thrombosis that occurred between 30 day and two-year follow up clearly confirms the long term safety profile of the stent platform.”